Tg Therapeutics (TGTX) Common Equity (2011 - 2026)

Tg Therapeutics' Common Equity history runs 16 years deep, the most recent figure standing at $583.1 million for Q1 2026.

• In Q1 2026, Common Equity rose 145.75% year-over-year to $583.1 million; the TTM figure through Mar 2026 stood at $583.1 million (up 145.75% YoY), while the FY2025 annual figure was $648.0 million, up 191.42% from the prior year.
• Common Equity for Q1 2026 stood at $583.1 million, down from $648.0 million in the prior quarter.
• The five-year high for Common Equity was $648.0 million in Q4 2025, with the low at $27.4 million in Q1 2023.
• The 5-year median for Common Equity is $170.4 million (2022), against an average of $232.7 million.
• The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 83.9% in 2023, then soared 483.64% in 2024.
• Tg Therapeutics' Common Equity stood at $58.6 million in 2022, then jumped by 173.95% to $160.5 million in 2023, then jumped by 38.54% to $222.4 million in 2024, then surged by 191.42% to $648.0 million in 2025, then decreased by 10.01% to $583.1 million in 2026.
• Business Quant data shows TGTX's Common Equity at $583.1 million in Q1 2026, $648.0 million in Q4 2025, and $607.2 million in Q3 2025.